Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
about
Low dose versus high dose stavudine for treating people with HIV infectionLow dose versus high dose stavudine for treating people with HIV infectionHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsA risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapyToxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapyPilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenReduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study.Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional studyLIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings.Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The NetherlandsEpidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapyEffectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaEffect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyHIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study
P2860
Q24186488-C4465ADE-0232-4C85-A2D1-3D6563445DC3Q24242088-D7A46B73-8B54-49CF-8562-B40B850FDFAAQ28088839-85EFD04C-7549-46F1-8920-5BBA5B45FB6BQ28477707-D1FEC26D-17BE-4D74-9347-BEF1EED22A44Q28478110-5AD01BDB-3F46-4AEE-8AA2-1CEBACC0F6BCQ28741214-779BAAD0-E211-4AC8-B6D3-9A9A9092AB8EQ33968248-269E9581-966A-48B1-979D-9ECA6BC1A855Q33968260-E03580A5-888E-43AB-8840-CAFA06C014F0Q34039225-68E88232-F1A2-47B6-8400-208223559B9BQ34058478-149CD865-5919-4DC4-A245-87CA8AA39604Q34840325-570F402B-FC17-4FCE-B89B-FD789FC6B942Q35010207-25E51459-7EA2-4B85-A7FF-D2F14F5240C0Q35594914-67C9F864-77D2-45F0-852D-1622B42E353DQ35856520-F2C62239-4E00-4160-A541-A237EE4C1177Q36558893-02924C2F-5320-45E5-942D-F06D8A9E834EQ36646867-E06BD1CB-8604-4B9B-9351-29CEA794C943Q36726178-A1E2EDEA-1A54-4771-8589-38B2D7AA824FQ37025001-6EA49B91-1F78-4414-A3DD-A3B5B15D4245Q37251569-213CC6F6-D691-4704-8DB4-16F41A9FF9ACQ37419984-0F82153F-4E92-48F8-B875-6233F14F861FQ37544710-80599F03-17B4-4FEE-ACB6-1C8A7392555FQ37828539-2FF18C7E-2AFE-456E-964C-38F69A5EBFF3Q37999051-E063A3B7-1726-4014-8443-419EC3415F5AQ41590742-6FCA1361-6F93-4753-B6DE-8C37D6214B6DQ42249729-00F03202-E4C9-4D13-9708-D2A9F6014846Q45815166-1DDFB919-8708-449B-A123-475B38E8FA08Q53695978-75C39273-C494-4C5A-BBBA-47684385BF3FQ58798902-0D256549-9117-4FD2-B086-5C462870EE0A
P2860
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Systematic review of clinical ...... t of antiretroviral treatment.
@ast
Systematic review of clinical ...... t of antiretroviral treatment.
@en
type
label
Systematic review of clinical ...... t of antiretroviral treatment.
@ast
Systematic review of clinical ...... t of antiretroviral treatment.
@en
prefLabel
Systematic review of clinical ...... t of antiretroviral treatment.
@ast
Systematic review of clinical ...... t of antiretroviral treatment.
@en
P2093
P2860
P50
P356
P1476
Systematic review of clinical ...... t of antiretroviral treatment.
@en
P2093
Andrew Hill
Jose Gatell
Mattana Hanvanich
P2860
P304
P356
10.1517/14656566.8.5.679
P407
P577
2007-04-01T00:00:00Z